PHASE II STUDY OF AMRUBICIN IN PATIENTS WITH REFRACTORY OR RESISTANT RELAPSED SMALL-CELL LUNG CANCER: JAPAN CLINICAL ONCOLOGY GROUP STUDY (JCOG0901)

被引：0
|
作者：
Daga, H. [1 ]
Murakami, H.
Yamamoto, N. [6 ]
Shibata, T. [3 ]
Endo, M. [2 ]
Watanabe, H. [4 ]
Ichinose, Y. [5 ]
Yamamoto, N. [6 ]
Ohe, Y. [7 ]
Tamura, T. [6 ]
机构：
[1] Osaka City Gen Hosp, Dept Clin Oncol, Osaka, Japan
[2] Shizuoka Canc Ctr, Dept Radiol, Shizuoka, Japan
[3] Natl Canc Ctr, Regulatory Sci Sect, Multiinst Clin Trial Support Ctr, Tokyo, Japan
[4] Natl Canc Ctr, Dept Radiol, Tokyo, Japan
[5] Kyushu Natl Canc Ctr, Dept Thorac Oncol, Fukuoka, Japan
[6] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[7] Natl Canc Ctr Hosp E, Kashiwa, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：492 / 492
页数：1
相关论文
共 50 条
  • [21] Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer
    Ettinger, David S.
    Jotte, Robert
    Lorigan, Paul
    Gupta, Vicram
    Garbo, Lawrence
    Alemany, Carlos
    Conkling, Paul
    Spigel, David R.
    Dudek, Arkadiusz Z.
    Shah, Chirag
    Salgia, Ravi
    McNally, Richard
    Renschler, Markus F.
    Oliver, Jennifer W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15) : 2598 - 2603
  • [22] Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer
    Lammers, Philip E.
    Shyr, Yu
    Li, Chung-I
    Hutchison, Anne Smith
    Sandler, Alan
    Carbone, David Paul
    Johnson, David H.
    Keedy, Vicki Leigh
    Horn, Leora
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : 559 - 562
  • [23] Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer
    Chiang, Anne C.
    Sequist, Lecia Van Dam
    Gilbert, Jill
    Conkling, Paul
    Thompson, Dana
    Marcoux, J. Paul
    Gettinger, Scott
    Kowanetz, Marcin
    Molinero, Luciana
    O'Hear, Carol
    Fasso, Marcella
    Lam, Sivuonthanh
    Gordon, Michael S.
    CLINICAL LUNG CANCER, 2020, 21 (05) : 455 - +
  • [24] Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402
    Nogami, Naoyuki
    Hotta, Katsuyuki
    Segawa, Yoshihiko
    Takigawa, Nagio
    Hosokawa, Shinobu
    Oze, Isao
    Fujii, Masanori
    Ichihara, Eiki
    Shibayama, Takuo
    Tada, Atsuhiko
    Hamada, Noboru
    Uno, Masatoshi
    Tamaoki, Akihiko
    Kuyama, Shoichi
    Ikeda, Genyo
    Osawa, Masahiro
    Takata, Saburo
    Tabata, Masahiro
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    ACTA ONCOLOGICA, 2012, 51 (06) : 768 - 773
  • [25] A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer
    Han, Ji-Youn
    Kim, Hyae Young
    Lim, Kun Young
    Han, Jong Hee
    Lee, You Jin
    Kwak, Mi Hyang
    Kim, Hak Jin
    Yun, Tak
    Kim, Heung Tae
    Lee, Jin Soo
    LUNG CANCER, 2013, 79 (02) : 137 - 142
  • [26] Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naIve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901
    Morikawa, Naoto
    Inoue, Akira
    Sugawara, Shunichi
    Maemondo, Makoto
    Harada, Toshiyuki
    Harada, Masao
    Fujita, Yuka
    Katoh, Terufumi
    Yokouchi, Hiroshi
    Watanabe, Hiroshi
    Usui, Kazuhiro
    Suzuki, Toshiro
    Sakakibara-Konishi, Jun
    Nagai, Hiroki
    Kanbe, Mariko
    Nukiwa, Toshihiro
    LUNG CANCER, 2017, 111 : 38 - 42
  • [27] Second-line chemotherapy with amrubicin for sensitive/refractory recurrent small-cell lung cancer (SCLC): A phase II study (#0301) by the thoracic oncology research group
    Takiguchi, Yuichi
    Masuda, Noriyuki
    Seto, Takashi
    Eguchi, Kenji
    Isobe, Hiroshi
    Okamoto, Hiroaki
    Ogura, Takashi
    Yokoyama, Akira
    Watanabe, Koshiro
    ANNALS OF ONCOLOGY, 2006, 17 : 220 - 220
  • [28] Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study
    Takashi Yana
    Shunichi Negoro
    Minoru Takada
    Soichiro Yokota
    Yoshiki Takada
    Takahiko Sugiura
    Hidehiko Yamamoto
    Toshiyuki Sawa
    Masaaki Kawahara
    Nobuyuki Katakami
    Yutaka Ariyoshi
    Masahiro Fukuoka
    Investigational New Drugs, 2007, 25 : 253 - 258
  • [29] Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern cooperative oncology group trial 1597
    Masters, GA
    Declerck, L
    Blanke, C
    Sandler, A
    DeVore, R
    Miller, K
    Johnson, D
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) : 1550 - 1555
  • [30] Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study
    Yana, Takashi
    Negoro, Shunichi
    Takada, Minoru
    Yokota, Soichiro
    Takada, Yoshiki
    Sugiura, Takahiko
    Yamamoto, Hidehiko
    Sawa, Toshiyuki
    Kawahara, Masaaki
    Katakami, Nobuyuki
    Ariyoshi, Yutaka
    Fukuoka, Masahiro
    INVESTIGATIONAL NEW DRUGS, 2007, 25 (03) : 253 - 258
12345